Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||The invention concerns an intravaginal device comprising a combination of 17 .beta.-estradiol and a supporting matrix for treating hypoestrogenic women. The device releases continuously 17 .beta.-estradiol at a rate of about 0.5 to about 25 .mu.g/24 h. The invention also comprises a method of preparing the device and a method of treating hypoestrogenic women by using the device.|
|Inventor(s):||Lindskog; Inga M. (Helsingborg, SE), Sjogren; Bengt C. H. (Viken, SE), Andersson; Sven-Borje (Od.ang.kra, SE)|
|Assignee:||Aktiebolaget Leo (Helsingborg, SE)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Sweden||8602666||Jun 16, 1986|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.